维莫非尼：在不可切除或转移性黑色素瘤中的应用指南。

Vemurafenib: a guide to its use in unresectable or metastatic melanoma.

机构信息

Adis, 41 Centorian Drive Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand.

出版信息

Am J Clin Dermatol. 2013 Feb;14(1):65-9. doi: 10.1007/s40257-012-0007-3.

Abstract

Oral vemurafenib (Zelboraf(®)) is a first-in-class, small molecule BRAF(V600E) inhibitor indicated for the treatment of unresectable or metastatic melanoma in BRAF(V600) mutation-positive patients (EU) or BRAF(V600E) mutation-positive patients (USA). Compared with intravenous dacarbazine, vemurafenib significantly improved overall survival and progression-free survival in patients with unresectable, previously untreated, BRAF(V600E) mutation-positive, stage IIIC or IV melanoma. Oral vemurafenib was generally well tolerated, with cutaneous adverse events among the most commonly occurring adverse events.

摘要

口服维莫非尼（Zelboraf(®)）是一种首创的小分子 BRAF(V600E)抑制剂，适用于治疗 BRAF(V600)突变阳性的不可切除或转移性黑色素瘤患者（欧盟）或 BRAF(V600E)突变阳性的患者（美国）。与静脉注射达卡巴嗪相比，维莫非尼可显著改善不可切除、未经治疗、BRAF(V600E)突变阳性、IIIC 期或 IV 期黑色素瘤患者的总生存期和无进展生存期。口服维莫非尼通常具有良好的耐受性，皮肤不良反应是最常见的不良反应之一。